LGD-4033 is a non-steroidal SARM (selective androgen receptor modulator). LGD-4033 is one of the only SARMs that has been researched for use in healthy male populations. The SARM LGD-4033 is currently being studied to see how well it is tolerated, how safe it is, and how it influences muscle size and performance in clinical trials.
If you have heard about LGD-4033, but you can’t remember why, perhaps the name Joakim Noah from the Knicks rings a bell. He is the NBA player who was suspended for 20 games after failing a drug test for having LGD-4033 in his system. Noah had levels of LGD-4033 in his system, which is an unapproved supplement.
Selective androgen receptor modulators target the AR (androgen receptor). The androgen receptor (NR3C4) is gene that activates onces it binds to androgenic hormones such as DHT, DHEA and DHEA, or testosterone.
In women, AR is responsible for regulating hair growth and sex drive, as well as can be converted to female hormones in women. Female androgens that convert to estrogen are produced in the female sex organs such as the ovaries. Androgens are also produced in fat cells and the adrenal glands.
Androgens are more commonly associated, however, with men when we think about them. Androgens in men are responsible for testosterone. Testosterone in the hormone that has been associated with male masculinity, such as build muscle and igniting sexual drive.
So how to SARMs like LGD-4033 affects these symptoms? Traditionally, hormone concerns, muscle loss and other age-related diseases, have been treated with testosterone, but testosterone is anabolic in nature. Anabolic testosterone treatments don’t just improve muscle wasting caused by age-related diseases and cancers. However, they also affect hormones and brain activity, which causes significant side effects. Researchers study SARMs for anabolic benefits without dangerous hormonal side effects.
Research and Reviews of LGD-4033
In 2013, research was conducted on 76 healthy male participants who were between the ages of 21 and 50 years. Researchers used the non-steroidal SARM LGD-4033 to observe and analyze the safety of the compound, the tolerability of the body, and the ability of the SARM to target muscle processes.
LGD-4033 was administered to participants for 21 days. The researchers continued to monitor hormone presence, lean mass, fat mass, and muscle strength for up to 5 weeks after the 21-day trial ended. The research revealed the participants tolerated the SARM LGD-4033 with no adverse drug-related side effects. The team discovered than using LGD-4033 for a limited time, just 21 days, saw increases in lean muscle mass. During this time, no change in prostate antigen occurred. REsearchers recommend longer studies for future research to better understand health outcomes and potential benefits of LGD-4033 in specific populations.
Overview of Benefits of LGD-4033
Studies on LGD-4033 report potential benefits of LGD-4033 in clinical studies:
- Increased lean muscle mass
- Improved bone density
- High tolerance
- Favorable pharmacokinetic profile
- Results with minimal use and lower dosage
- Hormone and lipid levels return after cycles stop
More research on LGD-4033 is needed to fully understand the benefits of LGD-4033 for clinical research purposes. Preliminary data does reflect increases in lean muscle mass; however, fat mass levels remained the same. More research is needed to understand why.